Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission : single-centre results after TBI-based myeloablative and non-myeloablative conditioning. / Sengeløv, H; Gerds, T A; Brændstrup, P; Kornblit, B; Mortensen, B K; Petersen, S L; Vindeløv, L L.
I: Bone Marrow Transplantation, Bind 48, Nr. 9, 09.2013, s. 1185-91.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission
T2 - single-centre results after TBI-based myeloablative and non-myeloablative conditioning
AU - Sengeløv, H
AU - Gerds, T A
AU - Brændstrup, P
AU - Kornblit, B
AU - Mortensen, B K
AU - Petersen, S L
AU - Vindeløv, L L
PY - 2013/9
Y1 - 2013/9
N2 - We report the results of non-myeloablative (NM) and myeloablative (MA) conditioning for haematopoietic cell transplantation in 207 consecutive AML patients at a single institution. A total of 122 patients were transplanted in first CR (CR1) and 67 in second CR (CR2). MA conditioning was given to 60 patients in CR1 and 50 in CR2. NM conditioning was given to 62 patients in CR1 and 17 patients in CR2. MA patients in CR1 experienced more acute GVHD than NM patients, 60.5% versus 22.9%, but the 5-year post transplant cumulative TRM was not different. Relapse incidence at 5 years in CR1 patients was 23.7% which is not statistically different from 28.5% in NM patients. Leukaemia-free survival at 5 years in CR1 patients was 57.7% after MA conditioning and 58.3% after NM conditioning. No statistical difference in overall 5-year survival after MA or NM conditioning was observed in CR1 patients (63.9 versus 64%) and CR2 patients (51.2 versus 64.7%). Durable remission can be obtained in older patients with AML in remission after NM conditioning, which may also be applicable to younger patients.
AB - We report the results of non-myeloablative (NM) and myeloablative (MA) conditioning for haematopoietic cell transplantation in 207 consecutive AML patients at a single institution. A total of 122 patients were transplanted in first CR (CR1) and 67 in second CR (CR2). MA conditioning was given to 60 patients in CR1 and 50 in CR2. NM conditioning was given to 62 patients in CR1 and 17 patients in CR2. MA patients in CR1 experienced more acute GVHD than NM patients, 60.5% versus 22.9%, but the 5-year post transplant cumulative TRM was not different. Relapse incidence at 5 years in CR1 patients was 23.7% which is not statistically different from 28.5% in NM patients. Leukaemia-free survival at 5 years in CR1 patients was 57.7% after MA conditioning and 58.3% after NM conditioning. No statistical difference in overall 5-year survival after MA or NM conditioning was observed in CR1 patients (63.9 versus 64%) and CR2 patients (51.2 versus 64.7%). Durable remission can be obtained in older patients with AML in remission after NM conditioning, which may also be applicable to younger patients.
KW - Adolescent
KW - Adult
KW - Combined Modality Therapy
KW - Cyclophosphamide
KW - Female
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Leukemia, Myeloid, Acute
KW - Living Donors
KW - Male
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Retrospective Studies
KW - Survivors
KW - Transplantation Conditioning
KW - Transplantation, Homologous
KW - Whole-Body Irradiation
KW - Young Adult
U2 - 10.1038/bmt.2013.38
DO - 10.1038/bmt.2013.38
M3 - Journal article
C2 - 23524638
VL - 48
SP - 1185
EP - 1191
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 9
ER -
ID: 134781561